{"id":473379,"date":"2021-04-08T01:03:20","date_gmt":"2021-04-08T05:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473379"},"modified":"2021-04-08T01:03:20","modified_gmt":"2021-04-08T05:03:20","slug":"addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/","title":{"rendered":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Geneva, Switzerland, April 8, 2021 <\/strong>\u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PnB3_q7SnocXwhKbpoq8zJYKEbD03MIh59wc9iNFrQ6YeY3liMNY-UsXKQBQPbmF2ONxDotoqG0x-CMC4eVDJtgloPnR0y5OjZLfxRLqnvk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Addex Therapeutics<\/a> Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has filed a registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) to provide flexibility for future offerings of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex. The terms of the future offerings have not been determined yet and there can be no assurance as to whether or when the offerings may be completed. Addex intends to file a prospectus supplement with the SEC, where required, to describe the specific terms of any such securities offering. <\/p>\n<p align=\"justify\">A registration statement on Form F-3 has been filed with the SEC but has not yet become effective. The securities referred to in the registration statement may not be sold, nor may offers to buy them be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. <\/p>\n<p align=\"justify\">\n        <strong>About Addex Therapeutics:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PnB3_q7SnocXwhKbpoq8zJmg2uM-PyobzgX8EssudekYf_gD28ZZK65K4Wcv9DjKYwL2h79K8EHFA9TFy4_u5hx5zSGwpSGqPxHrRBZgwINPtThKOMhGbfPBkMU5fsae\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>Addex Therapeutics\u00a0<\/u><br \/>\n        <\/a>is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional &#8220;orthosteric&#8221; small molecule or biological drugs. Addex&#8217;s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex&#8217;s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start \u00a0a pivotal registration clinical trial for Parkinson\u2019s disease levodopa induced dyskinesia (PD-LID) in 2021. Addex is also investigating dipraglurant&#8217;s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in 2021. Addex&#8217;s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in 2021. Addex\u2019s GABAB\u00a0PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABA<sub>B<\/sub>\u00a0PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson\u2019s disease and mGlu3 PAM for neurodegenerative disorders.<strong>\u00a0<\/strong><\/p>\n<p align=\"justify\">\n        <strong>Press Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:2065px;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\"> Tim Dyer<br \/>Chief Executive Officer<br \/>Telephone: +41 22 884 15 55<br \/>Email:\u00a0<a href=\"mailto:PR@addextherapeutics.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>PR@addextherapeutics.com<\/u><\/a><\/td>\n<td style=\"width:2085px;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\"> Mike Sinclair<br \/>Partner, Halsin Partners<br \/>+44 (0)20 7318 2955<br \/><a href=\"mailto:msinclair@halsin.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>msinclair@halsin.com<\/u><\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward Looking Statements:<\/strong><br \/>\n        <br \/>Statements in this announcement concerning the timing and terms of the anticipated offering of the Company\u2019s securities are forward-looking statements, which are subject to risks and uncertainties, including those risks described in the Company\u2019s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review.<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/de0da467-42c2-414c-ad45-de7c8bf3bf3c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Geneva, Switzerland, April 8, 2021 \u2013 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has filed a registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) to provide flexibility for future offerings of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex. The terms of the future offerings have not been determined yet and there can be no assurance as to whether or when the offerings may be completed. Addex intends to file a prospectus supplement with the SEC, where required, to describe the specific &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473379","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Geneva, Switzerland, April 8, 2021 \u2013 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has filed a registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) to provide flexibility for future offerings of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex. The terms of the future offerings have not been determined yet and there can be no assurance as to whether or when the offerings may be completed. Addex intends to file a prospectus supplement with the SEC, where required, to describe the specific &hellip; Continue reading &quot;Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T05:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission\",\"datePublished\":\"2021-04-08T05:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/\"},\"wordCount\":532,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/\",\"name\":\"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\",\"datePublished\":\"2021-04-08T05:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/","og_locale":"en_US","og_type":"article","og_title":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk","og_description":"Geneva, Switzerland, April 8, 2021 \u2013 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has filed a registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) to provide flexibility for future offerings of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex. The terms of the future offerings have not been determined yet and there can be no assurance as to whether or when the offerings may be completed. Addex intends to file a prospectus supplement with the SEC, where required, to describe the specific &hellip; Continue reading \"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T05:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission","datePublished":"2021-04-08T05:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/"},"wordCount":532,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/","name":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==","datePublished":"2021-04-08T05:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzA3NSM0MDA5MDc3NzkjMjAwMjU4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-files-registration-statement-on-form-f-3-with-the-us-securities-and-exchange-commission\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473379"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473379\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}